The National Institute for Health and Care Excellence (NICE) has approved teplizumab for use on the NHS for people with early-stage type 1 diabetes, marking the start of a new era in how we treat the ...

Dr Elizabeth Robertson, Diabetes UK's Director of Research and Clinical, shares her thoughts following the historic approval of the first type 1 diabetes immunotherapy on the NHS.

Type 2 diabetes causes Type 2 diabetes is high blood sugar levels caused by a lack of a hormone called insulin. Either your body isn’t making enough or the insulin it makes doesn’t work properly. This ...

Devastating diabetes complications costs the UK healthcare system £6.2 billion a year, which highlights not just the seriousness of diabetes but also the importance of getting the right care to people ...

UPDATE, 22 MAY 2024: We now have new information on the amount of people living with the diabetes, and for more information you can visit our guide on diabetes statistics. The number of people living ...

We take a look at some of the exciting diabetes research developments announced in October, and what the findings could mean for people living with or affected by diabetes.

Scientists in the United States have announced early results from a pioneering trial testing a new stem cell treatment designed to replace insulin-producing beta cells in people with type 1 diabetes.

We're going to explore whether an intermittent fasting diet can help you put your type 2 diabetes into remission. What are intermitten ...

In some areas of the UK, there are type 2 diabetes remission programmes available through the NHS and health boards. Not every area has a specific type 2 remission programme available, and where there ...

We take a look at some of the exciting diabetes research developments announced in March 2026, and what the findings could mean for people living with or affected by diabetes.

Our analysis has revealed that the number of children receiving treatment for type 2 diabetes in Paediatric Diabetes Units in England and Wales has increased by over 50%. We’re calling on the ...